The combination of two adenoviral vectors demonstrated safety and feasibility in patients with high-grade glioma and warrants further investigation in a phase 1b/2 clinical trial.
The combination of two adenoviral vectors demonstrated safety and feasibility in patients with high-grade glioma and warrants further investigation in a phase 1b/2 clinical trial.
For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Privacy Policy